Context Plasma homocysteine level has been recognized as an important cardiovascular risk factor that predicts adverse cardiac events in patients with established coronary atherosclerosis and influences restenosis rate after percutaneous coronary intervention.
D ESPITE TECHNICAL IMPROVEments, restenosis and overall adverse events after percutaneous coronary interventions remain important limitations of this procedure. 1 Epidemiological evidence suggests that total plasma homocysteine level is an independent cardiovascular risk factor, 2,3 correlates with the severity of coronary artery disease, 4, 5 predicts mortality in patients with established coronary atherosclerosis, 6, 7 and may have a potential role with regard to outcome after coronary interventions. Studies on the pathogenesis of homocysteine-induced vascular damage have suggested adverse interaction with vascular smooth muscle cells, 8, 9 endothelium function, 10, 11 plasma lipoproteins, 12 and coagulation cascade, [13] [14] [15] [16] which may contribute to homocysteineinduced atherogenesis, restenosis, and overall adverse events after coronary interventions, such as angioplasty.
Previous reports have documented that plasma homocysteine levels predict outcome after coronary angioplasty 17, 18 and our group has shown that homocysteine-lowering therapy significantly decreases restenosis rate after coronary angioplasty. 19 Based on those results, we now report in an extension of our original study, the effect of homocysteine-lowering therapy with folic acid, vitamin B 12 (cyanocobalamin), and vitamin B 6 (pyridoxine hydrochloride) on clinical outcome after successful coronary angioplasty and, in particular, whether the previously described 6 months' benefit is maintained at 1 year despite cessation of ho-mocysteine-lowering therapy at 6 months.
METHODS
The protocol was approved by the Institutional Research Ethics Committee of the University Hospital in Bern, Switzerland. Each patient gave written informed consent. This was a prospective study enrolling 553 consecutive patients from May 1998 to April 1999 who had undergone angioplasty of at least 1 significant coronary stenosis (Ն50%) (FIGURE 1) . After successful coronary angioplasty, patients were randomly assigned in double-blind fashion to receive folic acid (1 mg/d), vitamin B 12 (400 µg/d), and vitamin B 6 (10 mg/d) or placebo daily for 6 months. The study medication was formulated to obtain a maximal homocysteine-lowering effect with a minimal risk of adverse effects. 20 The study population included a subgroup of 205 patients independently randomized and scheduled for follow-up angiography at 6 months; the quantitative angiography results of this subgroup have been published. 19 Patients with unstable angina, subacute myocardial infarction (Ͻ2 weeks), renal insufficiency (serum creatinine level Ͼ1.8 mg/dL [160 µmol/L]), or taking vitamin supplements were not included. Patients were asked to withhold any multivitamin intake for the entire study duration. Fasting total plasma homocysteine levels were measured on admission and at 6 months follow-up using a rapid high-performance liquid chromatographic assay. 21 Coronary angioplasty was performed according to standard clinical practice, with success defined as residual diameter stenosis less than 35% with normal flow pattern (Thrombolysis in Myocardial Ischemia [TIMI] III trial criteria). 22
Angiographic Evaluation
Quantitative evaluation was carried out in monoplane projection after predilatation with nitrates. Two orthogonal views were averaged for biplane assessment. Data analysis was performed using an automated edge-detection system (Philips Integris-BH-3000, Version 2 [if online] or Philips View-Station-CDM-3500, Version 2 [if offline]; Philips, Best, the Netherlands) with an institutional intraobserver variability of 0.15 mm for minimal luminal diameter and 7% for stenosis severity. 19 The tip of the diagnostic or guiding catheter (positioned at the coronary ostium) was used for calibration purposes. The same views and calibration techniques were used for target lesion revascularization. End-diastolic frames in the 2 orthogonal views that demonstrated maximal stenosis severity were used for luminal diameter measurement. Reference vessel diameter, minimal luminal diameter, diameter stenosis, and lesion length were calculated as the average value of the 2 views. Angiograms were reviewed by an experienced interventional cardiologist blinded to patients' homocysteine level and treatment assignments.
Follow-up and Study End Points
Clinical follow-up, including noninvasive stress test and resting electrocardiogram, was performed at 6 months and 1 year, or earlier if symptoms recurred. Adverse events were defined prospectively as (1) death; (2) cardiac death, defined as sudden, unexplained death or death related to myocardial infarction; (3) nonfatal myocardial infarction, defined as new Q waves (Ͼ40 ms; Ͼ0.2 mV) in 2 or more contiguous electrocardiographic leads; (4) need for repeat revascularization for proven ischemia demonstrated by either follow-up cardiac events or a positive noninvasive stress test with significant angiographic stenosis of at least 50%; and (5) a composite of major adverse events defined as any of the above events. Patients with more than 1 event had only the first occurring event computed for overall major adverse events determination.
Statistical Analysis
The target sample size of 555 patients was based on the assumption that the rate of major adverse events would be 25% or more in the placebo-treated group and less than 15% in the group treated with folate+B 12 +B 6 . 17, 19 Assuming a 10% dropout rate, the planned sample size would yield 500 patients with complete follow-up and give the study a statistical power of 80% at a significance level of .05. 23 All analyses were performed with the intent-to-treat principle, and patients lost to follow-up were censored at the time clinical data became no longer available. Plasma homocysteine levels were positively skewed and therefore logtransformed prior to analysis. Results are shown in natural units. Categorical variables are reported as counts (percentages) and continuous variables as mean (SD). Categorical variables were examined by 2 test. Continuous variables were examined by a 2-tailed t test or by the Mann-Whitney U test if skewed. The Spearman rank correlation coefficient was used to estimate the correlation between homocysteine levels and different continuous variables.
Kaplan-Meier survival curves were used to evaluate freedom from major adverse events, and treatment effect differences were assessed with the Mantel-Cox log-rank test. Cox proportional hazards regression models were used to examine the relation between treatment groups and the different end points, after adjustment for multiple clinical and angiographic covariates including age, sex, use or nonuse of stent, treatment of restenotic or de novo lesions, vessel size, postprocedural minimal luminal diameter, target lesion location, and use or nonuse of glycoprotein IIb/IIIa inhibitors. Selected variables were those that were associated with at least 1 of the end points in unadjusted analysis. Cardiovascular risk factors (diabetes mellitus, hypertension, hypercholesterolemia, smoking status) and statin use were not associated with the different end points in unadjusted analysis. Furthermore, adjustment for those variables did not significantly modify the Cox proportional hazards regression analysis and were thus not included in the model. Patients with a history of renal failure (serum creatinine level, Ͼ1.8 mg/dL [160 µmol/L]) were not included to avoid elevated creatinine values as confounders for increased plasma homocysteine levels. PϽ.05 was considered statistically significant. Data were prospectively collected and analyzed using StatView Version 4.5 (SAS Institute, Cary, NC).
RESULTS
Five hundred fifty-three patients were randomly assigned either to receive folate+B 12 +B 6 (n = 272) or placebo (n = 281), with a total of 741 successfully treated lesions ( Figure 1 ). Seventy patients (110 lesions) were lost to follow-up or did not comply with the study protocol: 14 (6 in the folate+B 12 +B 6 group) discontinued study medication, 37 (15 in the folate+B 12 +B 6 group) refused noninvasive stress testing, 17 (8 in the folate+B 12 +B 6 group) with proven ischemia refused reangiography, and 2 (1 in the folate+B 12 +B 6 group) developed reversible contrast agent nephropathy. Two patients randomized to receive folate+B 12 +B 6 discontinued study medication because of pruritus. No other adverse effect was reported. The baseline clinical, laboratory, and angiographic characteristics of the 70 patients without complete follow-up did not significantly differ from the remaining study population. Given that clinical outcomes were the primary end points in this study, all analyses were performed with the intent-totreat principle.
Baseline Characteristics
Patients in the 2 groups were well matched at baseline with regard to demographic variables and cardiovascular risk factors (TABLE 1) . Severity of coronary artery disease (as measured by a history of previous myocardial infarction, previous revascularization, and the number of treated lesions per patient), baseline laboratory values, and discharge drug therapy were not sig- Lesion location was independent of study group: 40% of all lesions were located in the left anterior descending coronary artery and about 30% each in the circumflex coronary artery and the right coronary artery (TABLE 2) . 24 Lesion severity (lesion complexity, lesion length, vessel size, minimal luminal diameter, and diameter stenosis) before and after coronary angioplasty was comparable between study groups. The use of stents and glycoprotein IIb/IIIa inhibitors was also identical between study groups.
Study End Points
After a mean (SD) follow-up of 11 (3) .03) , and the restenotic nature of previously treated lesions (RR, 3.36; 95% CI, 1.67-6.76; P=.002). Adjustment for multiple risk factors including age, sex, and variables known to influence the need for target lesion revascularization after coronary angioplasty (use of stents, treatment of restenotic lesions, vessel size, postprocedural minimal luminal diameter, target lesion location, use of IIb/IIIa inhibitors) did not significantly change the association between homocysteine-lowering therapy and the need for repeat target lesion revascularization. In Cox proportional hazards regression analysis, only folate+B 12 +B 6 therapy (P = .02), the restenotic nature of previously treated lesions (P = .005), and postprocedural minimal luminal diameter (P = .01) retained statistical significance. The need for target lesion revascularization was independent of cholesterol levels, but the benefit of folate+ B 12 +B 6 therapy was most apparent for patients in the highest cholesterol tertile. Compared with controls, patients treated with folate+B 12 There was a nonsignificant trend for a lower incidence of nonfatal myocardial infarction (RR, 0.60; 95% CI, 0.24-1.51; P=.27), cardiac deaths (RR, 0.52; 95% CI, 0.13-2.04; P = .34), and overall deaths (RR, 0.54; 95% CI, 0.16-1.70; P = .27) in patients receiving folate+B 12 +B 6 therapy. Older age (SD) was the only variable significantly associated with mortality (65.4 [11.5] years vs 61.2 [10.8] years, P = .002).
The incidence of major adverse events was significantly lower in patients receiving folate+B 12 +B 6 therapy at 6 months (11.4% vs 18.9%; RR, 0.60; 95% CI, 0.40-0.91; P=.02) and at 1 year follow-up (15.4% vs 22.8%; RR, 0.68; 95% CI, 0.48-0.96; P=.03) (FIGURE 2) . Adjustment for the previously men-tioned variables did not significantly change this association (P=.01). These findings were reproduced in subgroups of patients stratified according to the traditional cardiovascular risk factors (sex, diabetes mellitus, hypertension, hypercholesterolemia, and smoking) (FIGURE 3) . The only other variable independently associated with the incidence of major adverse events was the restenotic nature of previously treated lesions (P=.008).
COMMENT
This study provides evidence that homocysteine-lowering therapy with folic acid, vitamin B 12 , and vitamin B 6 improves outcome after percutaneous coronary intervention by reducing the need for repeat revascularization and decreasing the overall incidence of major adverse events 1 year after successful coronary angioplasty. This benefit is primarily related to a decrease in target lesion revascularization, as the need for revascularization of lesions other than a target lesion was almost identical between study groups. Furthermore, these findings were reproduced in subgroups of patients stratified according to the traditional cardiovascular risk factors. Vessel size, postprocedural minimal luminal diameter, and treatment of restenotic lesions are known to influence the need for target lesion revascularization. 25, 26 These parameters were equally distributed between study groups and the benefit of folate+B 12 +B 6 therapy on the outcome after coronary angioplasty remained unaltered after adjustment for those risk factors. These results are consistent with those of recent randomized trials with homocysteine-lowering therapy showing decreased risk of atherosclerotic coronary events among healthy patients, 27 halting in the progression of carotid plaque, 28 improved arterial endothelial function, [29] [30] [31] and significant benefit on restenosis rate after coronary angioplasty. 19 This study further suggests that the benefit obtained with homocysteinelowering therapy at 6 months is maintained at 1 year despite cessation of folate+B 12 +B 6 therapy at 6 months. Our previously reported significant decrease in restenosis rate after coronary angioplasty 19 could have been questioned as a temporary benefit triggered by a homocysteine-lowering therapyrelated delay of the restenosis process. The rate of event-free survival was significantly higher among patients assigned to receive folate+B 12 The size of each data marker is proportional to the number of patients; horizontal bars represent 95% confidence intervals.
The current study confirms that a 6-month course of this inexpensive treatment has minimal adverse effects and helps to control excessive restenosis mechanisms. 32 The mechanisms by which elevated homocysteine levels impair vascular function and possibly influence outcome after percutaneous coronary intervention are not clearly understood, although several hypotheses have been suggested. Elevated homocysteine levels stimulate vascular smooth muscle cell growth 8, 9 and collagen synthesis, 33 which promote intimal-medial thickening. 34 Elevated homocysteine levels may also have a procoagulant effect through interaction with coagulation factor V, 13 protein C, 14 tissue plasminogen activator, 15 and tissue factor activity. 16 However, increasing evidence suggests that the primary mechanism may be oxidative-endothelial injury and dysfunction. 10, 11 Elevated homocysteine levels decrease the release of nitric oxide 35, 36 and promote the generation and accumulation of hydrogen peroxide, thus rendering nitric oxide more susceptible to oxidative inactivation. 34 Furthermore, elevated plasma homocysteine levels pro-mote lipid peroxidation, 37 which alters growth factor production and influences smooth muscle cell proliferation. 38 Oxidized LDL cholesterol has been shown to increase smooth muscle cells proliferation and chemoattraction 39, 40 and enhance platelet-derived growth factor gene expression and receptor formation in vascular smooth muscle cell. 41 Therefore, homocysteineinduced endothelial dysfunction and lipid peroxidation may promote smooth muscle cell proliferation, extracellular matrix formation, and ultimately increase the need for repeat target lesion revascularization. Our findings that the benefit of homocysteine-lowering therapy increases with higher levels of LDL cholesterol supports this possible mechanism.
A critical question is whether the benefit of homocysteine-lowering therapy on the outcome after coronary intervention reflects causality. In the current study, the treatment of restenotic lesions, the treatment of lesions in smaller vessels, and smaller postprocedural minimal luminal diameter were all significantly associated with a worse outcome after coronary angioplasty. Adjustment for these factors did not weaken the benefit of homocysteine-lowering therapy, suggesting an independent association.
A limitation of the study design was that it precluded assessment of the separate effects of folic acid, vitamin B 12 , and vitamin B 6 , and the effect of different doses of these vitamins. Furthermore, we cannot exclude the possibility that the benefit seen was not also influenced by other homocysteine-independent treatment effects. Specifically, folic acid likely improves nitric oxide availability independently of its homocysteinelowering effect, 42 and vitamin B 6 deficiency appears to be an independent predictor of coronary artery disease 43 and further has been shown to alter platelet function. 44 Therefore, and despite the findings of the Homocysteine Lowering Trialists' Collaboration group that vitamin B 6 does not significantly lower homocysteine levels, 20 the inclusion of vitamin B 6 in the homocysteine-lowering therapy or possibly another homocysteine-unrelated effect of folic acid or vitamin B 12 could have contributed to the improvement seen in the patients treated with folate+B 12 +B 6 . In conclusion, the findings in this study, in conjunction with our previously described association between homocysteine levels and restenosis rate, 17 support the conclusion that the combination of folic acid, vitamin B 12 , and vitamin B 6 , at least partially by lowering of homocysteine levels, is an effective therapy for improving outcome in patients undergoing coronary angioplasty.
